King Luther Capital Management Corp Buys 208,853 Shares of Johnson & Johnson $JNJ

King Luther Capital Management Corp lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 46.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 655,724 shares of the company’s stock after acquiring an additional 208,853 shares during the quarter. King Luther Capital Management Corp’s holdings in Johnson & Johnson were worth $121,584,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in JNJ. Avestar Capital LLC raised its holdings in Johnson & Johnson by 7.1% during the 3rd quarter. Avestar Capital LLC now owns 17,731 shares of the company’s stock worth $3,288,000 after purchasing an additional 1,181 shares during the last quarter. CFO4Life Group LLC increased its position in shares of Johnson & Johnson by 1.7% during the third quarter. CFO4Life Group LLC now owns 10,855 shares of the company’s stock worth $2,013,000 after buying an additional 179 shares during the period. Piedmont Capital Management LLC lifted its holdings in Johnson & Johnson by 2.7% in the third quarter. Piedmont Capital Management LLC now owns 5,585 shares of the company’s stock valued at $1,028,000 after buying an additional 147 shares during the period. L & S Advisors Inc boosted its position in Johnson & Johnson by 365.9% during the third quarter. L & S Advisors Inc now owns 40,854 shares of the company’s stock valued at $7,575,000 after acquiring an additional 32,086 shares during the last quarter. Finally, Synovus Financial Corp grew its holdings in Johnson & Johnson by 2.5% during the 3rd quarter. Synovus Financial Corp now owns 230,188 shares of the company’s stock worth $42,686,000 after acquiring an additional 5,653 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on JNJ shares. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a research note on Thursday, January 22nd. Loop Capital set a $220.00 price target on Johnson & Johnson in a report on Tuesday, January 27th. Sanford C. Bernstein lifted their price objective on shares of Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a research note on Friday, January 23rd. Barclays boosted their target price on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 30th. Finally, Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $233.73.

Johnson & Johnson Stock Up 0.6%

Johnson & Johnson stock opened at $244.89 on Thursday. The firm has a market capitalization of $590.17 billion, a price-to-earnings ratio of 22.16, a price-to-earnings-growth ratio of 2.36 and a beta of 0.35. The firm’s fifty day moving average price is $219.71 and its two-hundred day moving average price is $198.21. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $246.35. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion during the quarter. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Announced a >$1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Pennsylvania as part of a multi‑year U.S. manufacturing expansion — expands capacity for JNJ’s cell/biologic pipeline and signals long‑term revenue growth potential. Read More.
• Positive Sentiment: FDA approved a simplified monthly dosing schedule for RYBREVANT FASPRO (amivantamab + hyaluronidase), improving convenience for EGFR+ NSCLC patients and potentially boosting uptake and product competitiveness. Read More.
• Positive Sentiment: Received FDA Breakthrough Therapy Designation for subcutaneous amivantamab (RYBREVANT FASPRO) in advanced head & neck cancer — could speed development and improve commercial prospects if confirmatory data follow. Read More.
• Positive Sentiment: Raised the quarterly dividend to $1.30 (annualized $5.20), reinforcing the shareholder‑yield profile that supports income‑oriented ownership. Read More.
• Neutral Sentiment: Options activity around JNJ has increased, which can amplify short‑term moves; useful for traders but not a fundamental driver by itself. Read More.
• Neutral Sentiment: Small contract extension with Trellus Health keeps a patient‑support program in place — operationally positive but immaterial to overall revenue. Read More.
• Negative Sentiment: Insider selling: two executive vice presidents disclosed sizable stock sales this week (Vanessa Broadhurst sold ~6,197 shares at ~$243.39; Timothy Schmid sold ~22,623 shares at ~$244.33). Large insider sales can weigh on sentiment even if motivated by diversification or tax planning. Read More.
• Negative Sentiment: Ongoing talc litigation and recent verdict coverage keep legal risk and potential liabilities on the radar — this continues to cap valuation upside despite operational wins. Read More.

Insider Activity at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares in the company, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.